Beta-Alanine
|
Basic information |
| Metabolite name | Beta-Alanine |
 | HMDB0000056 |
 |
C00099 |
 |
239 |
| Synonyms | β-alanine; |
| No. of studies | 23 |
|
Basic information |
| Metabolite name | Beta-Alanine |
| HMDB0000056 |
|
C00099 |
|
239 |
| Synonyms | β-alanine; |
| No. of studies | 23 |
|
Relationship between Beta-Alanine and depression (count: 23) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M019 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M022 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M034 | Type1 | MDD group vs. control group | Urine | Human | Up |
| Study M045 | Type1 | CUMS group vs. control group | Peripheral blood mononuclear cell | Sprague-Dawley rat | Down |
| Study M054 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M065 | Type1 | depressed group vs. control group | Plasma | Human | Down |
| Study M083 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M096 | Type1 | CUMS group vs. control group | Plasma | Wistar rat | Down |
| Study M096 | Type1 | CUMS group vs. control group | Hippocampus | Wistar rat | Up |
| Study M096 | Type2 | CUMS + paroxetine group vs. CUMS group | Plasma | Wistar rat | Up |
| Study M105 | Type1 | sCSDS group vs. control group | Plasma | C57BL/6JJmsSlc mouse | Up |
| Study M1055 | Type1 | depression group vs. control group | Urine | Human | Down |
| Study M130 | Type2 | CSDS + DG group vs. CSDS group | Prefrontal cortex | C57BL/6 mouse | Up |
| Study M130 | Type2 | CSDS + venlafaxine group vs. CSDS group | Prefrontal cortex | C57BL/6 mouse | Up |
| Study M181 | Type3 | venlafaxine group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M474 | Type1 | olfactory bulbectomy group vs. control group | Plasma | C57BL/6J mouse | Down |
| Study M492 | Type1 | ACTH group vs. control group | Urine | Wistar rat | Down |
| Study M492 | Type2 | ACTH + memantine group vs. ACTH group | Urine | Wistar rat | Up |
| Study M492 | Type2 | ACTH + CGA group vs. ACTH group | Urine | Wistar rat | Up |
| Study M536 | Type1 | naturally-occurring depression group vs. control group | Cerebrospinal fluid | Cynomolgus monkey | Up |
| Study M648 | Type1 | ART-treated HIV with depressive symptom group vs. ART-treated HIV without depressive symptom group, discovery cohort | Plasma | Human | Up |
| Study M663 | Type3 | diterpene ginkgolides group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M671 | Type1 | CUMS group vs. control group | Striatum | Sprague-Dawley rat | Up |
| Study M712 | Type1 | depression group vs. control group | Serum | Cynomolgus monkey | Down |
| Study M712 | Type1 | depression group vs. control group | Faece | Cynomolgus monkey | Up |
| Study M882 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M882 | Type1 | CUMS group vs. control group | Jejunum | Sprague-Dawley rat | Down |
| Study M908 | Type3 | post-ketamine treatment vs. baseline | Plasma | Human | Up |
| Study M928 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M962 | Type2 | 24h-post ketamine infusion vs. baseline | Plasma | Human | Up |